Business Wire

PSA-CERTIFIED

4.4.2024 10:01:28 CEST | Business Wire | Press release

Share
PSA Certified Announces New PSA Certified Level 4 Certification and Continued Partner Growth

PSA Certified, the global security and evaluation framework for the connected device ecosystem, has today announced its highest certification level to date as it accelerates its mission to build assurance in connected devices. The new PSA Certified Level 4 iSE/SE certification offers enhanced protection of high value assets that can secure valuable AI models, future-proofing systems against new attack methods and rising security threats linked to the rapid adoption of edge AI. Its launch follows a period of strong momentum for PSA Certified which has become a trusted route for demonstrating security best practice and the assurance of connected devices.

David Maidment, Senior Director, Secure Devices Ecosystem at Arm (a PSA Certified co-founder):

As the world embraces a new set of AI-enabled use cases, the value of data and assets has never been higher; nor has the importance of protecting them. The launch of PSA Certified Level 4 iSE/SE is testament to our commitment to helping the industry deploy security features that will protect devices and models from malicious changes and theft now, as well as over the next decade.”

As security cements its position as a business imperative, forward-looking companies are uplevelling their investment in security-by-design. PSA Certified has now surpassed the milestone of 200 certifications from nearly 90 technology providers, making it one of the most successful schemes to address connected device security.

The newly launched PSA Certified Level 4 Integrated Secure Enclave / Secure Element (iSE/SE) certification, already available at PSA Certified Labs, builds on the scheme’s momentum further and underpins a step change that can be used to protect valuable models and data during device boot and at rest (when models reside in secure storage). The level recognizes the use of a highly robust integrated Secure Enclave (iSE) or Secure Element (SE) - that acts as a trusted subsystem to the full Root of Trust (PSA RoT). By safeguarding critical cryptographic functions and key storage, OEMs can now ask for a RoT with a trusted subsystem that offers a ‘high’ level of attack resistance.

Benefits of PSA Certified Level 4 iSE / SE Certification include:

Protecting ML models at rest with highly robust crypto and key storage

  • PSA Certified Level 4 iSE/SE considers more sophisticated attack methods in scope. Chips that achieve this new level could be used in an AI context to help protect valuable models and data at boot and rest: some chips will need protection from advanced fault injection and differential power analysis (up to and including EMFI, single laser and multi-glitching). PSA Certified Level 4 iSE/SE chips will also benefit from stronger cryptography of at least 128-bit strength. The new level offers a “high” level of protection of the PSA-RoT assets from physical or software attack.
  • A trusted subsystem that achieves PSA Certified Level 4 iSE/SE can be used through composition in a PSA Certified Level 3+SE certification of the full PSA RoT security functionality. The PSA Certified Level 3 document has been updated to allow this new certification level.

PSA Certified Level 4 iSE/SE will help protect emerging use cases from sophisticated security attacks

  • PSA Certified Level 4 iSE/SE offers additional security against more advanced attacks. Chips that offer this RoT provide a strong trust anchor that could be used to decrypt and verify OTA updates which help protect models in high-value systems.
  • Industrial and safety-critical use cases need to support system recovery and stronger authentication: re-establishing integrity, confidentiality and availability are fundamental when rebooting systems and deploying OTA updates when faults are found, or upgrades are required. PSA Certified iSE/SE also mandates higher strength cryptography, which protects against more sophisticated attacks.
  • Trust anchor for Edge AI and infrastructure chips, providing a “High” level of protection against physical and software attacks on critical assets that require a more robust Root of Trust to maintain system integrity.

A transparent certification scheme with a route to High, Substantial, and Basic levels of robustness and assurance, purpose-built for the SoC market

  • PSA Certified offers a variety of robustness levels to match the market’s needs, all specifically designed for the electronics industry. By allowing a trusted subsystem to be certified as a component, and that certificate reused as part of a complete PSA RoT many times, chip vendors benefit from significant time and cost savings.

The first partner to aim for the PSA Certified Level 4 iSE/SE standard is Infineon, showcasing its commitment to developing IoT devices to the highest security-by-design standards.

Erik Wood, Senior Director, IoT Secure MCU Products at Infineon comments:

“In the age of AI, the risks of insecurity are immense and increasing. I’ve backed PSA Certified since launch and I am impressed by its success in uniting the technology ecosystem around the common goal of improving trust and security within the connected device ecosystem, while aligning to emerging government standards and legislation. The launch of PSA Certified Level 4 iSE/SE takes that one step further. With this new level, the electronics industry is better able to protect against the growing advancement of attack methods driven by the explosion of machine learning, generative AI and LLM.”

About PSA Certified

PSA Certified is a global partnership of security-conscious companies who are proactively building security best practices into devices at scale. Our security framework and independent third-party evaluation scheme was originally spearheaded by Arm and six other security ecosystem leaders (and now maintained by Applus+ Laboratories, CAICT, ECSEC Laboratory, ProvenRun, Riscure, SGS Brightsight, Serma, TrustCB, and UL) providing the resources needed to build upon the Root of Trust.

PSA Certified has scaled to become one of the fastest growing, most valued security ecosystems, globally. Being awarded ‘Ecosystem of the Year’ in the IoT Global Awards 2021 is testament to the role it has played in uniting industry, standards bodies, regulators and insurers together under one initiative. In doing so it’s accelerating the cross-industry collaboration required to untap the full potential of the IoT.

With 200 certifications from 88 partners, PSA Certified has democratized the adoption of security across the electronics industry, giving the ecosystem the confidence to innovate, while protecting consumers from the most common hacks.

Find out more: psacertified.org

1A Certified Security Report 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404517921/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye